Actively Recruiting
Sepsis-associated Thrombocytopenia and Platelet Transfusion （STAPT）
Led by Nanfang Hospital, Southern Medical University · Updated on 2026-01-30
1500
Participants Needed
1
Research Sites
71 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Currently, there are no multicenter studies on platelet transfusion for SAT patients, and the benefits and risks of platelet transfusion still require further validation based on large-sample data. In summary, investigating the correlation between platelet transfusion during ICU stay and 28-day mortality in SAT patients, as well as evaluating the impact of platelet transfusion on bleeding, thrombotic events, and inflammation control, is of great significance for optimizing SAT management strategies. This study aims to analyze the effect of platelet transfusion on the prognosis of SAT patients, thereby providing an evidence-based foundation for clinical decision-making.
CONDITIONS
Official Title
Sepsis-associated Thrombocytopenia and Platelet Transfusion （STAPT）
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients admitted to the ICU between January 2021 and May 2024 and subsequently discharged
- Age 18 years or older
- Diagnosis of sepsis following Sepsis-3.0 criteria
- Platelet count below 100 × 10⁹/L at ICU admission
- ICU stay lasting 48 hours or longer
You will not qualify if you...
- Active major bleeding such as gastrointestinal bleeding or intracranial hemorrhage
- Blood cancers including leukemia, myelodysplastic syndrome, or lymphoma
- Liver cirrhosis classified as Child-Pugh B or C
- Chronic kidney disease at stage 4 or 5
- Autoimmune diseases like systemic lupus erythematosus
- Chemotherapy, immunosuppressant treatment, or organ/bone marrow transplant within 2 weeks
- Pregnancy or breastfeeding
- Chronic low platelet count (below 100 × 10⁹/L) for more than 1 month
- Long-term use of antiplatelet or anticoagulant medications for over 2 weeks
- Significant blood clotting problems at ICU admission (prolonged PT or APTT, low fibrinogen)
- APACHE II score of 30 or higher within 24 hours of ICU admission
- Missing over 20% of key clinical data including platelet counts and ICU survival status
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nanfang Hospital， Southern Medical University
Guangzhou, Guangdong, China, 510515
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here